Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1 1

Status

Completed 2

Sponsor Class

OTHER 5NIH 2

Study Type

Interventional 2

Sponsor

Cancer Type

Plasma cell 2Breast 1

Conditions

Multiple Myeloma 2Neoplasms, Plasma Cell 1

Interventions

Dexamethasone 36Melphalan 29Cyclophosphamide 28Specimen Handling 26Biopsy 26Bortezomib 24Calcium Dobesilate 20Magnetic Resonance Spectroscopy 19Lenalidomide 17fludarabine phosphate 15Filgrastim 15Peripheral Blood Stem Cell Transplantation 13Vincristine 12Prednisone 12dexamethasone acetate 11dexamethasone 21-phosphate 11auricularum 11carfilzomib 10Doxorubicin 10sargramostim 9fludarabine 8Thalidomide 8Interferon-alpha 7Cyclosporine 7Busulfan 7trametinib 6ixazomib 6Rituximab 6Etoposide 6daratumumab 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
NIH × Pamidronate × Plasma cell × Clear all
NCT00033332 2014-04-04

Dexamethasone With or Without Thalidomide in Treating Patients With Newly Diagnosed Multiple Myeloma

National Cancer Institute (NCI)

Phase 3 Completed
Plasma cell

Multiple Myeloma, Neoplasms, Plasma Cell

NCT00124605 2013-01-07

Arsenic Trioxide and Pamidronate in Treating Patients With Advanced Solid Tumors or Multiple Myeloma

National Cancer Institute (NCI)

Phase 1 Completed
24 enrolled
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡